Influence of storage temperature on indomethacin release from fatty-base suppositories in vitro and in vivo.

Toshiko Yoshida*  
Yoshinori Itoh†  
Yutaka Gomita‡  
Ryozo Oishi**

*Okayama University,  
†Okayama University,  
‡Okayama University,  
**Okayama University,
Influence of storage temperature on indomethacin release from fatty-base suppositories in vitro and in vivo.*

Toshiko Yoshida, Yoshinori Itoh, Yutaka Gomita, and Ryozo Oishi

Abstract

The release of indomethacin from fatty-base suppositories, which had been stored at a low (4 degrees C) and a high (25-30 degrees C) temperature for about one month, was examined in vitro and in vivo. In the in vivo experiments, the plasma indomethacin levels after administration of suppositories stored at different temperatures were measured in conscious and anesthetized rats. In the in vitro release test using a dialysis cell method, much lower amounts of indomethacin were released from the suppositories stored at a high temperature than from those stored at a low temperature. The melting point of suppositories stored at a high temperature was higher by approximately 2 degrees C than those stored at a low temperature. In conscious rats, the plasma indomethacin levels attained after the intrarectal administration of suppositories stored at a high temperature were slightly lower than those after the animals were given suppositories stored at a low temperature, but the difference was significant only 30 min after administration. In anesthetized rats, the plasma indomethacin levels were markedly lower than those in conscious rats, and the influence of the storage temperature on the plasma indomethacin levels was clearly observed. These results suggest that in conscious rats many factors such as a locomotor hyperactivity and enhancement of gastrointestinal motility caused by the rectal administration mask the real character of suppositories. The in vitro and in vivo results show that the release of indomethacin from fatty-base suppositories stored at a high temperature is less than the release from those stored at a low temperature.

KEYWORDS: indomethacin, suppository, quality control, bioavailability, in vitro release test

*PMID: 2063694 [PubMed - indexed for MEDLINE]
Copyright (C) OKAYAMA UNIVERSITY MEDICAL SCHOOL
Influence of Storage Temperature on Indomethacin Release from Fatty-Base Suppositories *In Vitro* and *In Vivo*

Toshiko Yoshida, Yoshinori Itoh, Yutaka Gomita* and Ryozo Oishi*

*Department of Pharmacology and *Hospital Pharmacy, Okayama University Medical School, Okayama 700, Japan*

The release of indomethacin from fatty-base suppositories, which had been stored at a low (4°C) and a high (25-30°C) temperature for about one month, was examined in *vitro* and in *vivo*. In the *in vivo* experiments, the plasma indomethacin levels after administration of suppositories stored at different temperatures were measured in conscious and anesthetized rats. In the *in vitro* release test using a dialysis cell method, much lower amounts of indomethacin were released from the suppositories stored at a high temperature than from those stored at a low temperature. The melting point of suppositories stored at a high temperature was higher by approximately 2°C than those stored at a low temperature. In conscious rats, the plasma indomethacin levels attained after the intrarectal administration of suppositories stored at a high temperature were slightly lower than those after the animals were given suppositories stored at a low temperature, but the difference was significant only 30 min after administration. In anesthetized rats, the plasma indomethacin levels were markedly lower than those in conscious rats, and the influence of the storage temperature on the plasma indomethacin levels was clearly observed. These results suggest that in conscious rats many factors such as a locomotor hyperactivity and enhancement of gastrointestinal motility caused by the rectal administration mask the real character of suppositories. The *in vitro* and *in vivo* results show that the release of indomethacin from fatty-base suppositories stored at a high temperature is less than the release from those stored at a low temperature.

*Key words:* indomethacin, suppository, quality control, bioavailability, *in vitro* release test

Suppositories for antitumor, anticonvulsant, analgesic-antipyretic and anti-inflammatory agents are widely used because of certain therapeutic advantages inherent in this method of administration, such as avoidance of gastrointestinal irritation and first-pass elimination (1, 2). Indomethacin is one of the drugs most frequently used in suppository form. Quality control of suppositories is always required since drugs released from this form of preparation are influenced by many factors. The storage of suppositories at a high temperature causes a rise in the melting point and a decrease in the rate of release of the drugs. Although there are several *in vitro* tests to determine the quality of suppositories, such as drug-release rate (3–7), melting characteristics (8),

*To whom correspondence should be addressed.
liquefaction time (9) and reological properties (10, 11), the data obtained from these in vitro experiments do not always parallel those from in vivo bioavailability tests using conscious animals (12, 13). In the present experiments, therefore, we studied in vitro the quality of fatty-base suppositories, which had been stored at low and high temperatures, and compared the results of in vitro studies with the data on bioavailability of indomethacin from these suppositories in conscious and anesthetized rats.

Materials and Methods

Materials. Commercial fatty-base suppositories of indomethacin (Sawai Chemical Co., Osaka, Japan) were used. The fatty-base consisted of Witexol. They were stored at a low (4°C) or at (25–30°C) room temperature in summer for about one month. The indomethacin contents in the suppositories were not changed after these storage periods. Pure indomethacin was donated by Sumitomo Chemical Co. (Takarazuka, Japan). Sodium pentobarbital and phenobarbital were obtained from Dainippon Pharmaceutical Co. (Osaka) and Sankyo Pharmaceutical Co. (Tokyo, Japan), respectively. Other chemicals used were of analytical or reagent grade, obtained from Wako Pure Chemical Industries (Osaka) and Toyo Chemicals (Tokyo).

In vitro release experiments. The release of indomethacin from the suppositories was measured by the Paddle method (Japanese Pharmacopoeia XI) modified by Fukuda et al. (14), in which a cellophane dialysis tubing was used instead of a basket and the dissolution medium was 900 ml of artificial plasma (pH 7.4 ± 0.1). At various times after the start of the experiment, 3 ml of medium of the compartment outside the cellulose tube was transferred to a glass cell for determination of indomethacin concentration by ultraviolet spectrophotometry at 254 nm.

In vivo experiments. Male Wistar rats weighing 190–210 g (Shizuoka Experimental Animals, Hamamatsu, Japan) were fasted for 24 h before the experiment. The suppositories cut in sizes corresponding to 40 mg/kg of indomethacin were inserted into the rectum, and the anuses were closed with alkyl-α-cyanoacrylate monomer (Aron Alpha, Sankyo Co., Tokyo). Some rats were anesthetized with an intraperitoneal injection of sodium pentobarbital (20 mg/kg) combined with phenobarbital (100 mg/kg). They were treated with indomethacin 15 min after the loss of righting reflex and put on a plate maintained at a temperature of 37°C.

At various times after the rectal administration of an indomethacin suppository, a 60-μl blood sample was taken into a heparinized capillary tube from the tail vein of each rat. The blood was immediately centrifuged at 12,000 rpm for 3 min. To 20 μl of plasma an appropriate amount of butylparaben was added as an internal standard. The mixture was applied to a Bond Elute C18 column (1 ml column volume, Analytichem International, USA). After the column was washed twice with 1 ml of distilled water, indomethacin and butylparaben were eluted with 250-μl methanol. A 20-μl aliquot of the eluate was injected into a high performance liquid chromatograph. Plasma indomethacin concentration was determined using a calibration curve made from the ratios of the indomethacin peak area to that of the internal standard. The high performance liquid chromatography system (Waters, Millipore, Tokyo) was composed of a pump (Model M 45 J), a spectrophotometer (Model 440 UV), an injector (Model 710 B WISP), a recorder (Data module type 730) and a reverse phase column (μ-Bondapak C18; 3.9 × 300 mm). The mobil phase was a mixture of 0.1% H3PO4-CH3CN (45:55 v/v). The flow rate was 1.5 ml/min, and the effluent was monitored at 254 nm.

Determination of melting point. The apparatus used for determination of the melting point of suppositories is described in the Japanese Pharmacopoeia XI. The immersion fluid used was water. Each suppository (1 cm in length) was inserted into a capillary tube opened at both ends. After heating, the time required for each sample to melt in the capillary tube was determined.

Statistical analysis. The data were evaluated for statistical significance by analysis of variance (ANOVA) and Student’s t-test.

Results

In vitro release of indomethacin from suppository. The time courses of increases in indomethacin concentration in the compartment outside the cellulose tube which contained a suppository stored at a low or a high temperature are shown in Fig. 1. The indomethacin concentrations increased almost linearly for the first 90-min period.
The rate of release from suppositories stored at a low temperature was approximately twice that from suppositories stored at a high temperature.

*Plasma indomethacin concentration after rectal administration of suppository.* Fig. 2 shows the plasma indomethacin concentrations in conscious rats after the rectal administration of indomethacin suppositories stored at a low or a high temperature. The indomethacin concentrations increased up to 4h after administration and remained relatively high even after 12h. The means values for the indomethacin concentration in rats treated with suppositories stored at a high temperature were lower at all times examined than the values in rats treated with suppositories stored at a low temperature. However, when the indomethacin concentrations in these groups were analyzed by ANOVA, the difference was not found to be significant (F = 2.73, p > 0.05). A significant difference according to Student's t-test was observed only 30min after the administration of suppositories (t = 3.91, p < 0.01).

Fig. 3 shows the effect of the storage temperature of suppositories on the plasma indomethacin concentrations after the rectal administration in anesthetized rats. The plasma indomethacin concentrations in anesthetized rats were 27–35% of those in conscious rats, 0.5–2h after administration (Figs. 2 and 3). In anesthetized rats, the administration of suppositories stored at a high temperature resulted in markedly lower plasma indomethacin levels than the corresponding values observed after the administration of suppositories stored at a low temperature (F = 7.18, p < 0.01).
results reported by Yoshino et al. (19), who showed by the dialysis-cell method that the rate of release of brilliant blue from suppositories decreased with an elevation in storage temperature.

Ayres et al. (12) showed that the rate of in vitro release from suppositories containing various concentrations of 
$^{3}$H-benzocaine roughly correlated with the in vivo bioavailability in rats. Vidras et al. (13) reported that the correlation between the rate of in vitro indomethacin release from various kinds of suppository bases and their in vivo bioavailability in rabbits was observed only at the initial period after administration into the rectum. In general agreement with these results, in the present experiments, when conscious rats were administered indomethacin suppositories stored at either a low or a high temperature, a significantly lower plasma indomethacin concentration was observed in animals given suppositories stored at a high temperature 30 min after treatment. However, the differences were generally slight as compared with those observed in the in vitro experiment. To determine the reason for the difference between the data obtained in the in vitro and in vivo experiments, we examined the bioavailability of indomethacin in anesthetized rats. In such animals, plasma indomethacin concentrations were markedly lower than the corresponding values observed in conscious animals. This was probably due to decreased absorption of indomethacin resulting from reductions in gastrointestinal motility and regional blood flow caused by anesthesia (20). Notwithstanding the low plasma indomethacin levels attained in anesthetized rats, a clear difference in the bioavailability of indomethacin as shown by the different plasma indomethacin levels was observed between animals given suppositories stored at a low and a high temperature.

Möes et al. (8) and Liversidge et al. (18) have demonstrated that the storage of fatty-base suppositories at a high temperature causes polymorphic changes and thereby results in an elevation of the melting point. Yoshino et al. (19) have also shown by X-ray diffraction analy-

---

**Discussion**

Drug release from fatty-base suppositories is influenced by many factors such as size of drug particles, solubility of drugs and melting point of bases (6, 15-18). Therefore, quality control of suppositories is important. In this study, we have examined the properties of suppositories both in vitro and in vivo tests.

In the in vitro test using cellulose membrane, the release of indomethacin from suppositories stored at a low temperature was significantly faster than that from suppositories stored at a high temperature, which is consistent with the
sis, that the initial unstable crystal form in the suppository bases changed to a more stable crystal form after long term storage at a high temperature. In the present experiments, the melting points of suppositories at a low temperature were significantly lower than the values for suppositories stored at a high temperature, which is consistent with the results reported previously.

The results obtained in the present study suggest that although the rate of in vivo release of indomethacin from fatty-base suppositories is decreased by a high storage temperature, locomotor hyperactivity and enhanced gastrointestinal motility caused by the rectal administration of suppositories may increase the rate of melting of the suppositories and the absorption of indomethacin in conscious rats. Therefore, the difference between the rates of in vivo release of indomethacin from suppositories stored at a low and a high temperature may have been decreased in conscious rats. Because patients who take indomethacin suppositories are generally required to lie quietly, the difference in bioavailability of indomethacin between suppositories stored at different temperatures may be more marked than that expected from the results of experiments using conscious rats.

In conclusion, the present in vitro and in vivo experiments on fatty-base suppositories containing indomethacin show that storage at a high temperature decreases the rate of release and bioavailability of the drug from suppositories.

Acknowledgements. We wish to thank Professors K. Saeki and Y. Araki of Okayama University for their helpful advice and discussion.

References


20. Conway CM and Ellis DB: The haemodynamic effects of